News NHS drug deal could fund vital cystic fibrosis research - Ve... Vertex wants long-term funding for CF research
Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
Views & Analysis Four new rare disease treatments awaiting NICE review Following yesterday’s international Rare Disease Day, here is a snapshot of four new rare disease treatments currently under review by England’s cost-effectiveness watchdog.
News Call for new restrictions on UK vaccine prices Proposals also include fresh attack on drug prices
News Eisai disappointed after NICE rejects earlier use for breast... NICE says no to Halaven in second line breast cancer
News NICE recommends funding for three thyroid cancer drugs Eisai's drug finally funded after two year delay
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
